Sanj K. Patel was appointed President and Chief Executive Officer and elected as a director of Synageva in June 2008. He created the vision and strategy for Synageva, launched its focus on rare diseases, and designed and initiated its lead program (Kanuma®) for LAL Deficiency in July 2008. He took the company public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in 5 years.
In May 2015, Synageva agreed to be acquired by Alexion for $8.4B (net of cash), which represented the highest premium ever paid for a biotech company valued over $5B.
Sanj has more than 20 years of experience in the pharmaceutical and biotech industries and has a combination of scientific, clinical and commercial skills. He joined Synageva from Genzyme Corporation (1999-2008) where most recently he was head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics’ Lysosomal Storage Disorder franchise and led the U.S. launch of Myozyme in addition to sales and marketing responsibility for Cerezyme, Fabrazyme and Aldurazyme. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Notably, Sanj led the Fabrazyme clinical operations team and development program to FDA approval in April 2003.
Prior to Genzyme, Sanj held roles in clinical research and commercial operations with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa Pharmaceuticals. Sanj obtained his BSc with Honors in Pure and Applied Biology (Biotechnology) from the University of the South Bank, London. He completed his post-graduate management and business degree, and doctorate level research program at Ealing College, London, and the Wellcome Foundation, respectively. Sanj is a member of the Board of Directors for the Sarcoma Foundation of America and Intercept Pharmaceuticals, Inc.